Latest Headlines

  1. Proliant Health & Biologicals Raises The Albumin Standard With AlbufreeDX: Consistent, Animal-Free Recombinant Human Albumin 6/24/2026

    Proliant Health & Biologicals announces the commercial launch of AlbufreeDX, a recombinant human albumin (rHA) designed to meet the growing demand for high-performance, animal-free ingredients across diagnostic and life science applications.

  2. Asimov Launches Chrysalis Transposase, A Wholly-Owned Genome Integration Tool For Biotherapeutics Production 6/23/2026

    Asimov announces Chrysalis transposase, a proprietary genome integration tool engineered to deliver higher titers, greater expression stability, and faster cell recovery than conventional transposases.

  3. Avance Clinical Announces Asia Pacific And Mainland China Expansion Ahead Of BIO International Convention 2026 6/23/2026

    Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a significant expansion of its Asia Pacific and China operations, reinforcing its position as the leading CRO partner for international biotech companies seeking access to the region’s diverse patient populations, scientific infrastructure, and accelerated clinical trial timelines.

  4. The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) Makes Breakthroughs Break Through As Boreal Biomanufacturing 6/18/2026

    The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is becoming Boreal Biomanufacturing (Boreal). 

  5. Minaris Enhances GMP Cell Banking Suites At Philadelphia Facility 6/18/2026

    Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization, today announced the enhancement of its dedicated GMP cell banking suites at its Philadelphia facility, a centralized hub for cell banking and biosafety testing. 

  6. Leica Biosystems And CellCarta Expand Collaborative Companion Diagnostic Development Model To Accelerate Commercialization Globally 6/1/2026
  7. Andelyn Biosciences Establishes The Andelyn Foundation To Support Families Living With Rare And Ultra-Rare Diseases 5/29/2026

    Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the unveiling of The Andelyn Foundation, a nonprofit organization dedicated to supporting families living with rare and ultra-rare diseases through awareness, fundraising, and compassionate community engagement.

  8. Andelyn Biosciences Launches LVV Curator® Platform, Bringing Proven Viral Vector Platform Pedigree To Lentiviral Vector Manufacturing For Cell Therapies 5/29/2026

    Andelyn Biosciences, a leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced the launch of its LVV Curator® Platform, a standardized lentiviral vector (LVV) manufacturing solution built on the same proven modular approach that supports clinical and commercial adeno-associated virus (AAV) programs.

  9. Andelyn Biosciences Receives Dark Horse Consulting Certification Of Gene Therapy Manufacturing Systems And Capabilities Within Its Initiative For Certification Of Manufacturing Capabilities (ICMC™) Program 5/29/2026

    Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced it has received full certification under the Initiative for Certification of Manufacturing Capabilities (ICMC) program from Dark Horse Consulting, recognizing the company’s capability to support advanced therapies manufacturing with its quality and production systems.

  10. Minaris Expands Rapid Mycoplasma Detection Services With bioMérieux's BIOFIRE® Platform To Reduce Turnaround Time For Release And In-Process Testing 5/27/2026

    Minaris Advanced Testing now offers an additional rapid PCR mycoplasma testing method to support accelerated lot release for advanced therapies and reduce overall development and manufacturing timelines.